Xilio Therapeutics

XLO · Nasdaq · United States

Share price · XLO

$7.63-1.87 (-19.68%) 3M

close as of 2026-11-18 · 24h delayed · vol 9K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when XLO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 3 Nov 2026+8.6%
  2. 27 Oct 2026+9.6%
  3. 14 May 2026+13.5%
  4. 5 May 2026-7.4%

    Nothing announced by XLO that day or the session before.

  5. 24 Mar 2026+6.5%
  6. 20 Mar 2026+7.8%
  7. 12 Feb 2026+11.4%
  8. 21 Jan 2026-4.6%
  9. 9 Jan 2026-6.0%
  10. 20 Nov 2025-7.1%

Share of unusual movement by asset

For each asset, the share of XLO's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
XTX501
events and moves
2shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—60%
Sessions with no dated event—39%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
PD-1/PD-L1 axis; IL-2 receptor βγ (IL-2Rβγ)Multispecific antibody
Non-Small Cell Lung Cancer

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
November 2029 (1)
XTX501Phase 1/2Metastatic NSCLC - Non-Small Cell Lung Cancer, Advanced Solid Tumor
Est. primary completion 2029-11 · NCT07688577 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$10.0M$15M$124M$6.0M-$14M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$19M$15M$138M$6.4M-$19M operating cash flowreport ↗
2026-Q1$13M$20M$152M$9.5M-$22M operating cash flowreport ↗
2025-Q3$19M$14M$106M$16M-$17M operating cash flowreport ↗
2025-Q2$8.1M$15M$123M$16M-$14M operating cash flowreport ↗
2025-Q1$2.9M$8.3M$91M$13M$29M operating cash flowreport ↗
2024-Q3$2.3M$11M$63M$14M-$14M operating cash flowreport ↗
2024-Q2$2.4M$11M$77M$14M$20M operating cash flowreport ↗
2024-Q1—$10M$37M$17M-$11M operating cash flowreport ↗
2023-Q3—$11M$61M$17M-$13M operating cash flowreport ↗
2023-Q2—$13M$77M$19M-$17M operating cash flowreport ↗
2023-Q1—$16M$95M$23M-$25M operating cash flowreport ↗
2022-Q3—$13M$141M$20M-$20M operating cash flowreport ↗
2022-Q2—$16M$161M$25M-$17M operating cash flowreport ↗
2022-Q1—$15M$179M$21M-$21M operating cash flowreport ↗
2021-Q3—$10M$101M$16M-$21M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$44M$56M$139M$8.8M-$5.0M operating cash flowreport ↗

Xilio reported full-year 2025 revenue of $43.77M, up 590.4% YoY, with R&D spend of $56.04M, up 36.0% YoY. Cash and equivalents totaled $139.34M, and the company recorded a net loss of $35.04M, with a quarterly net burn of $35.04M.

Management guided that existing cash should fund operations through the end of 2027, excluding potential milestone payments and up to $36.2M in Series C warrant proceeds. XTX501 remains on track for an IND submission in mid-2026 and Phase 1 initiation in the second half of 2026, while masked T cell engager programs targeting CLDN18.2 and PSMA/STEAP1 are advancing, with new CLDN18.2 preclinical data planned for AACR. The efarindodekin alfa Phase 2 trial continues, with an option data package to Gilead expected in the first half of 2027, and the company noted recent warrant exercises, an AbbVie milestone, and a February 2026 follow-on offering.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$6.3M$41M$57M$15M-$18M operating cash flowreport ↗
2023-FY—$52M$46M$19M-$69M operating cash flowreport ↗
2022-FY—$59M$122M$22M-$76M operating cash flowreport ↗
2021-FY—$51M$200M$19M-$81M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($44K), 2 sales ($6K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-10-01Houvras Yariv · CHIEF MEDICAL OFFICERAward / grant (derivative)105,000——Form 4
2026-06-11Brennan Aoife · directorAward / grant (derivative)5,000——Form 4
2026-06-11Bonstein Sara · directorAward / grant (derivative)5,000——Form 4
2026-06-11ROSS ROBERT W. · directorAward / grant (derivative)5,000——Form 4
2026-06-11Xu Yuan · directorAward / grant (derivative)5,000——Form 4
2026-06-11Curran Daniel J. · directorAward / grant (derivative)5,000——Form 4
2026-06-11Shannon James Samuel · directorAward / grant (derivative)5,000——Form 4
2026-06-11Bello Akintunde Olatokumbo · directorAward / grant (derivative)5,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 23 reporting institutions held 2.0M shares ($16.4M, 27.9% of shares outstanding).

#InstitutionSharesValue
1Bain Capital Life Sciences Investors, LLC664,021$5.6M
2Frazier Life Sciences Management, L.P.422,505$3.6M
3Sio Capital Management, LLC152,464$1.3M
4VANGUARD CAPITAL MANAGEMENT LLC123,660$1.0M
5Caligan Partners LP112,128$943K
6Merck & Co., Inc.105,982$891K
7Stonepine Capital Management, LLC64,162$540K
8MORGAN STANLEY57,493$484K
9RENAISSANCE TECHNOLOGIES LLC49,566$417K
10AJU IB Investment Co., Ltd.47,695$401K
11GEODE CAPITAL MANAGEMENT, LLC37,197$313K
12FMR LLC36,558$307K
13VANGUARD FIDUCIARY TRUST CO28,475$239K
14Velan Capital Investment Management LP14,285$120K
15Ghisallo Capital Management LLC13,800$116K